StreetInsider.com News Articles

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board (“DSMB”) has completed the second scheduled interim review of the Company’s ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary, non-hallucinogenic neuroplastogen,

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Wed, 04 Mar 2026 07:30:00 +0000

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial

Clearmind Medicine reports positive safety data from CMND-100 trial

Mon, 09 Feb 2026 08:17:23 +0000

Clearmind Medicine Inc. (NASDAQ: CMND) reported additional positive safety results from the second cohort of its Phase I/IIa clinical trial evaluating CMND-100 for alcohol use disorder treatment. The company said the results from six patients reinforce the drug candidate's safety and tolerability profile.

The trial data showed no serious adverse events and overall good tolerability, consistent with results from the first cohort. The company's Data and Safety Monitoring Board previously provided unanimous approval to advance to the second cohort.

The multinational, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder.

Clearmind Medicine reports positive safety data from CMND-100 trial

Mon, 09 Feb 2026 08:17:23 +0000

The multinational, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder.

Clearmind Medicine reports positive safety data from CMND-100 trial

Mon, 09 Feb 2026 08:17:23 +0000

The multinational, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder.

Clearmind Medicine reports positive safety data from CMND-100 trial

Mon, 09 Feb 2026 08:17:23 +0000

The multinational, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder.

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Mon, 09 Feb 2026 08:17:00 +0000

These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort,

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Fri, 12 Dec 2025 08:32:00 +0000

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a review article validating the therapeutic promise of its proprietary candidate, MEAI (5-methoxy-2-aminoindane, also known as CMND-100), in combating alcohol use disorder (AUD).

Entitled "The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder", the peer-reviewed review was published on December 2, 2025, in Current